We are currently looking to understand the pharma distribution strategy adopted by orphan drug (drugs to treat rare disease) manufacturers in australia. We know that australian market is dominated by three major cso distributors (api, sigma and x
b) and major generic drug manufacturers prefer to engage with these 3 wholesalers as they have the maximum distribution point of sales and are required to supply drugs listed in pbs.
1. So based on this, would like to know if orphan drug manufacturers also use these wholesalers or do they prefer direct distribution using dhl or world couriers, or any other strategy?
2. Would like to get some case specific to orphan drug distribution in australia.
Thank you and looking forward.
+undefined Other Responses
Drug Prep And Infusion
Looking for experts who understand the drug preparation and/or infusion spaces (specifically closed system transfer devices, iv filters, and iv drip chambers). Specifically, we are looking for people who have experience using, evaluating, or designing these devices and ideally with non-aqueous drugs such as hazardous alcohol containing chemotherapeutics and/or lipid containing solutions such as total parenteral nutrition (tpn).
We are looking for someone who can answer:
- when do these devices fail?
- are there issues with leakage or failure of these devices, specifically through the vent on the device, which could include blockage of the vent, wetting of the venting membrane, or actual liquid escaping?
- how significant is this problem? In what circumstances does it arise? What are the current solutions?
- are we seeing a trend in the occurrence of this issue?
- how are regulators looking at this issue?
We would be interested in talking to:
- end users such as clinical pharmacists, oncology nurses, hospital technicians, outpatient oncology nurses, technicians, and pharmacists
- regulators or regulatory consultants who have specific interest or experience in drug preparation and infusion devices
- designers or manufacturers of the components of these devices or the devices themselves (cstds, iv filters, drip chambers)
we need to have these conversations within the next 3 weeks and are looking for as many good interviews as we can possibly get+undefined Other Responses
Indian Generic Drugs Space
We are a global consulting firm currently working on a mandate in the indian generic drugs space.
We are looking to connect with experts having extensive prior experience in the strategy, commercial and r&d functions of indian generic manufacturers with presence in usa retail market and having own api manufacturing setup.
Experience/knowledge of the following topics:
- emerging and high growth areas (therapeutic areas or api product type) in the api space in india and other emerging markets, the us and european market.
- capabilities required to succeed in specific markets and specific therapeutic areas.
- overview on key players in api generics space and various business models adopted by large, midsize and small players (e.G., api focus with formulation add-on's, therapeutic area focus).
Please respond with your relevance to this request and your availability for a paid phone consultation this week.+undefined Other Responses
Complex Generic Drugs
I am an independent researcher specializing in the pharmaceutical space. Currently, i'm looking to speak with someone that has regulatory and/or manufacturing experience with complex generic drugs. More specifically, i'm looking at topical hormone creams. Ideally, this person would be knowledgeable on the companies who have these products in development and knowledgeable of the regulatory and/or manufacturing hurdles they have experienced. The ideal person may be someone within these companies or a consultant with this specialty. +undefined Other Responses